Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for OCUL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 520.04M
March 31, 2026 581.57M
December 31, 2025 654.31M
September 30, 2025 258.23M
June 30, 2025 305.92M
March 31, 2025 265.93M
December 31, 2024 315.34M
September 30, 2024 352.02M
June 30, 2024 377.70M
March 31, 2024 407.98M
December 31, 2023 91.13M
September 30, 2023 7.853M
June 30, 2023 3.087M
March 31, 2023 9.711M
December 31, 2022 35.38M
September 30, 2022 46.23M
June 30, 2022 65.80M
March 31, 2022 79.80M
December 31, 2021 88.00M
September 30, 2021 87.34M
June 30, 2021 80.25M
March 31, 2021 83.41M
December 31, 2020 76.10M
September 30, 2020 -4.126M
June 30, 2020 5.344M
Date Value
March 31, 2020 -10.66M
December 31, 2019 -3.63M
September 30, 2019 11.30M
June 30, 2019 8.258M
March 31, 2019 25.65M
December 31, 2018 35.88M
September 30, 2018 45.52M
June 30, 2018 45.73M
March 31, 2018 49.18M
December 31, 2017 26.15M
September 30, 2017 35.92M
June 30, 2017 48.02M
March 31, 2017 63.90M
December 31, 2016 52.01M
September 30, 2016 62.29M
June 30, 2016 70.45M
March 31, 2016 80.17M
December 31, 2015 89.59M
September 30, 2015 98.81M
June 30, 2015 109.11M
March 31, 2015 52.07M
December 31, 2014 58.70M
September 30, 2014 65.60M
June 30, 2014 4.92M
March 31, 2014 10.75M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
EyePoint, Inc. 166.41M
LENZ Therapeutics, Inc. 219.26M
Merck & Co., Inc. 41.93B
Theravance Biopharma, Inc. 289.70M
ANI Pharmaceuticals, Inc. 597.21M

Shareholders Equity (Quarterly) Related Metrics